Adipotide (FTPP)

WHAT IT IS

Adipotide combines a short targeting sequence that binds receptors, including prohibitin, found on blood vessels feeding white adipose tissue, with a pro-apoptotic peptide segment that induces localized cell death once it reaches its target.

It was developed at MD Anderson Cancer Center, building on earlier mouse research showing that ablating the blood supply to fat tissue could reduce fat mass. It was later licensed by a company, Ablaris Therapeutics, for potential human development.

It is a peptidomimetic, meaning it mimics peptide structure and function but is engineered rather than a naturally occurring hormone fragment. It is not a peptide sold for general research use in the same sense as many others in this library, and it is not an approved medicine. FDA status: Adipotide has never been FDA-approved and its clinical development has reportedly been discontinued.

WHAT RESEARCHERS ARE STUDYING IT FOR

The published research program on Adipotide focused on:

• Targeted destruction of blood vessels supplying white adipose tissue in obese rhesus and other Old World monkeys
• Resulting reductions in body weight, body mass index and waist circumference over weeks of treatment
• Improvements in insulin resistance measures in treated obese monkeys
• Dose-dependent, reversible changes in kidney proximal tubule function observed across three monkey species

PROPOSED BIOLOGICAL MECHANISMS

The homing portion of the molecule binds selectively to markers on the vasculature of white fat, directing the attached pro-apoptotic peptide specifically to those blood vessels rather than throughout the body.

Once localized, that segment disrupts vessel structure, cutting off blood supply to nearby fat cells, which are then reabsorbed and metabolized by the body.

This vascular-targeting strategy was originally explored in cancer research before being adapted for adipose tissue, and it explains why Adipotide behaves differently from receptor-based peptide hormones used elsewhere in metabolic research.

AREAS OF RESEARCH INTEREST

• Whether targeted vascular ablation is a viable long-term strategy for reducing fat mass in humans
• How to separate the desired fat-vessel effect from off-target effects on other tissues, particularly the kidney
• Whether the renal proximal tubule changes seen in monkeys would be tolerable, reversible or dose-limiting in humans
• Why clinical development appears to have stalled since the primate results were published

WHAT THE EVIDENCE CURRENTLY SUGGESTS

The strongest evidence for Adipotide comes from a 2011 peer-reviewed primate study, a step above rodent-only data because primates are biologically closer to humans, in which obese monkeys lost an average of roughly 11 percent of body weight over four weeks and showed improved insulin resistance.

The same study reported predictable, dose-related and reversible changes in kidney proximal tubule function across the three monkey species tested, an adverse finding the researchers themselves flagged as important for any future human development.

There is no published evidence that Adipotide has completed human clinical trials, and public reporting indicates its clinical development track has not advanced since the primate work, as of the most recent published information.